116 related articles for article (PubMed ID: 30070770)
1. Open-Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently.
Ambery C; Young G; Fuller T; Georgiou A; Ramsay D; Puri A; Daley-Yates P
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):188-197. PubMed ID: 30070770
[TBL] [Abstract][Full Text] [Related]
2. Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination.
Ambery C; Riddell K; Daley-Yates P
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):399-407. PubMed ID: 27170445
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD.
Crim C; Gotfried M; Spangenthal S; Watkins M; Emmett A; Crawford C; Baidoo C; Castro-Santamaria R
BMC Pulm Med; 2020 May; 20(1):119. PubMed ID: 32366249
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
Chen X; Zheng X; Jiang J; Hu P; Wu K; Zhuang L; Liu L; Du X; Kempsford R; Allen A
Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
[TBL] [Abstract][Full Text] [Related]
5. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.
Brealey N; Gupta A; Renaux J; Mehta R; Allen A; Henderson A
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):753-64. PubMed ID: 26227101
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination.
Allen A; Murdoch RD; Bareille P; Burns O; Hughes S; Gupta A; Miller SR
Clin Pharmacol Drug Dev; 2016 May; 5(3):225-31. PubMed ID: 27163502
[TBL] [Abstract][Full Text] [Related]
8. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
Nakahara N; Wakamatsu A; Kempsford R; Allen A; Yamada M; Nohda S; Hirama T
Int J Clin Pharmacol Ther; 2013 Aug; 51(8):660-71. PubMed ID: 23735179
[TBL] [Abstract][Full Text] [Related]
9. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
Yang S; Lee L; Mallett S; Ayer J; Wolstenholme A; Pascoe S
Adv Ther; 2015 Feb; 32(2):157-71. PubMed ID: 25700806
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2 -agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers.
Norris V; Ambery C; Riley T
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):305-13. PubMed ID: 27128837
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
Mehta R; Moore A; Riddell K; Joshi S; Chan R
J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):332-338. PubMed ID: 28463040
[TBL] [Abstract][Full Text] [Related]
12. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate.
Allen A; Bareille PJ; Rousell VM
Clin Pharmacokinet; 2013 Jan; 52(1):37-42. PubMed ID: 23184737
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Excretion, and Mass Balance of [
Ambery C; Young G; Fuller T; Lazaar AL; Pereira A; Hughes A; Ramsay D; van den Berg F; Daley-Yates P
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):901-910. PubMed ID: 30230263
[TBL] [Abstract][Full Text] [Related]
14. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
Kempsford R; Allen A; Bareille P; Hamilton M; Cheesbrough A
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):2-11. PubMed ID: 27127998
[TBL] [Abstract][Full Text] [Related]
15. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
Adachi M; Goldfrad C; Jacques L; Nishimura Y
Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
[TBL] [Abstract][Full Text] [Related]
17. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
Allen A; Davis A; Hardes K; Tombs L; Kempsford R
Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
Medley H; Orozco S; Allen A
Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
Oliver A; VanBuren S; Allen A; Hamilton M; Tombs L; Inamdar A; Kempsford R
Clin Ther; 2014 Jun; 36(6):928-939.e1. PubMed ID: 24793536
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
